CX 301
Alternative Names: CX-301Latest Information Update: 04 Jun 2024
At a glance
- Originator Cenyx Biotech
- Class Enzymes; Vascular disorder therapies
- Mechanism of Action Enzyme replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Stroke; Unspecified
Most Recent Events
- 24 Apr 2024 Preclinical trials in Stroke in South Korea (Parenteral) before April 2024 (Cenyx Biotech pipeline, April 2024)
- 24 Apr 2024 Preclinical trials in Unspecified in South Korea (Parenteral) before April 2024 (Cenyx Biotech pipeline, April 2024)